New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
Samuel Strober
Immunologist
Professor of Medicine (Immunology and Rheumatology)
Professional Education
- Internship: Massachusetts General Hospital (1967) MA
- Residency: Stanford University School of Medicine (1971) CA
- Fellowship: Oxford University (1965) UK
- Residency: Massachusetts General Hospital (1967) MA
- Medical Education: Harvard Medical School (1966) MA
Publications
-
Path to clinical transplantation tolerance and prevention of graft versus host disease.
Strober, S. (2014). Path to clinical transplantation tolerance and prevention of graft versus host disease. Immunologic Research, 58(2-3). -
Requirement for interactions of natural killer T cells and myeloid derived suppressor cells for transplantation tolerance
Hongo, D., Tang, X., Baker, J., Engleman, E. G., & Strober, s. (2014). Requirement for interactions of natural killer T cells and myeloid derived suppressor cells for transplantation tolerance. AJT, 14(11). -
Treatment of 4T1 metastatic breast cancer tumors with combined hypofractionated radiation and autologous T cell transplantation infusion
Filatenkov, A., Baker, J., Ahn, G. O., Kohrt, H., Dutt, S., & Strober, S. (2014). Treatment of 4T1 metastatic breast cancer tumors with combined hypofractionated radiation and autologous T cell transplantation infusion. Radiation Research, 182(2). -
Chimerism, graft survival, and withdrawal of immunosupressive drugs in HLA matched and mismatched patients after kidney and hematopoietic cell transplantation
Scandling, J. D., Busque, S., Shizuru, J. A., Lowsky, R., Hoppe, R., & Strober, S. (2014). Chimerism, graft survival, and withdrawal of immunosupressive drugs in HLA matched and mismatched patients after kidney and hematopoietic cell transplantation. AJT.
-
Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice
Tang, X., Jarrell, J. A., Price, J. V., Dai, H., Utz, P. J., & Strober, S. (2014). Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice. J Autoimmun, 50.
-
Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., & Lowsky, R. (2013). Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. CLINICAL IMMUNOLOGY, 148(1), 124-135.
-
Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line
Parker, J. J., Jones, J. C., Strober, S., & Knox, S. J. (2013). Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. CLINICAL IMMUNOLOGY, 148(1), 44-55.
-
Uniform Long-Term Graft Survival in a Clincial Trial of the Induction of Tolerance to Kidney Transplants.
Scandling, J., Busque, S., Shori, A., Dejbakhsh-Jones, S., Shizuru, J., & Strober, S. (2013). Uniform Long-Term Graft Survival in a Clincial Trial of the Induction of Tolerance to Kidney Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 13, 200-200.
-
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-disease
Meyer, E. H., Hsu, A. R., Liliental, J., Lohr, A., Zehnder, M., & Negrin, R. S. (2013). A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-disease. Blood, 121(24).
-
Rare cells predict GVHD.
Strober, S., & Lowsky, R. (2012). Rare cells predict GVHD. Blood, 119(21), 4820-4821.
-
Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., & Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133-1145.
-
Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants
Hongo, D., Tang, X., Dutt, S., Nador, R. G., & Strober, S. (2012). Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. BLOOD, 119(6), 1581-1589.
-
Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.
Kohrt, H. E., Müller, A., Baker, J., Goldstein, M. J., Newell, E., & Strober, S. (2011). Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood, 118(19), 5319-5329.
-
Selective Resistance of CD44(hi) T Cells to p53-Dependent Cell Death Results in Persistence of Immunologic Memory after Total Body Irradiation
Yao, Z., Jones, J., Kohrt, H., & Strober, S. (2011). Selective Resistance of CD44(hi) T Cells to p53-Dependent Cell Death Results in Persistence of Immunologic Memory after Total Body Irradiation. JOURNAL OF IMMUNOLOGY, 187(8), 4100-4108.
-
Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction
Strober, S., Spitzer, T. R., Lowsky, R., & Sykes, M. (2011). Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction. SEMINARS IN IMMUNOLOGY, 23(4), 273-281.
-
CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD
Dutt, S., Baker, J., Kohrt, H. E., Kambham, N., Sanyal, M., & Strober, S. (2011). CD8(+)CD44(hi) but not CD4(+)CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. BLOOD, 117(11), 3230-3239.
-
NKT cells, Treg, and their interactions in bone marrow transplantation
Kohrt, H. E., Pillai, A. B., Lowsky, R., & Strober, S. (2010). NKT cells, Treg, and their interactions in bone marrow transplantation. EUROPEAN JOURNAL OF IMMUNOLOGY, 40(7), 1862-1869.
-
Induced Tolerance to Rat Liver Allografts Involves the Apoptosis of Intragraft T Cells and the Generation of CD4(+)CD25(+)FoxP3(+) T Regulatory Cells
Fujiki, M., Esquivel, C. O., Martinez, O. M., Strober, S., Uemoto, S., & Krams, S. M. (2010). Induced Tolerance to Rat Liver Allografts Involves the Apoptosis of Intragraft T Cells and the Generation of CD4(+)CD25(+)FoxP3(+) T Regulatory Cells. LIVER TRANSPLANTATION, 16(2), 147-154.
-
The Changed Balance of Regulatory and Naive T Cells Promotes Tolerance after TLI and Anti-T-Cell Antibody Conditioning
Nador, R. G., Hongo, D., Baker, J., Yao, Z., & Strober, S. (2010). The Changed Balance of Regulatory and Naive T Cells Promotes Tolerance after TLI and Anti-T-Cell Antibody Conditioning. AMERICAN JOURNAL OF TRANSPLANTATION, 10(2), 262-272.
-
Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
Filatenkov, A., Mueller, A. Ms., Tseng, W. W.-L., Dejbakhsh-Jones, S., Winer, D., & Strober, S. (2009). Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation. JOURNAL OF IMMUNOLOGY, 183(11), 7196-7203.
-
beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus
Morshed, S. R., Takahashi, T., Savage, P. B., Kambham, N., & Strober, S. (2009). beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. CLINICAL IMMUNOLOGY, 132(3), 321-333.
-
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.
-
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4(+)CD25(+)Foxp3(+) T regulatory cells that protects against graft-versus-host disease
Pillai, A. B., George, T. I., Dutt, S., & Strober, S. (2009). Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4(+)CD25(+)Foxp3(+) T regulatory cells that protects against graft-versus-host disease. BLOOD, 113(18), 4458-4467.
-
Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2(hi) NKT cells
Yao, Z., Liu, Y., Jones, J., & Strober, S. (2009). Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2(hi) NKT cells. EUROPEAN JOURNAL OF IMMUNOLOGY, 39(3), 763-775.
-
Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: Role of natural killer T cells
Liu, Y. P., Li, Z., Nador, R. G., & Strober, S. (2008). Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: Role of natural killer T cells. TRANSPLANTATION, 85(4), 607-614.
-
Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., & Strober, S. (2008). Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 358(4), 362-368.
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation
Strober, S. (2008). Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. BLOOD CELLS MOLECULES AND DISEASES, 40(1), 48-54.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.